Sage Therapeutics (NASDAQ:SAGE) Receives Neutral Rating from HC Wainwright

HC Wainwright restated their neutral rating on shares of Sage Therapeutics (NASDAQ:SAGE) in a research note issued to investors on Wednesday morning,Benzinga reports. They currently have a $12.00 target price on the biopharmaceutical company’s stock, down from their previous target price of $14.00.

Several other research firms have also recently weighed in on SAGE. Oppenheimer reduced their price target on Sage Therapeutics from $9.00 to $8.00 and set a “market perform” rating on the stock in a report on Wednesday, October 30th. TD Cowen reduced their target price on Sage Therapeutics from $10.00 to $9.00 and set a “hold” rating on the stock in a report on Thursday, November 21st. StockNews.com cut Sage Therapeutics from a “hold” rating to a “sell” rating in a report on Thursday, October 31st. Needham & Company LLC reiterated a “hold” rating on shares of Sage Therapeutics in a report on Wednesday, November 20th. Finally, Royal Bank of Canada upgraded Sage Therapeutics from an “underperform” rating to a “sector perform” rating and set a $4.00 target price on the stock in a report on Thursday, November 21st. Three research analysts have rated the stock with a sell rating, sixteen have assigned a hold rating and two have given a buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $9.65.

Sage Therapeutics Trading Down 0.4 %

Shares of NASDAQ SAGE opened at $7.16 on Wednesday. The company has a market cap of $437.98 million, a price-to-earnings ratio of -1.28 and a beta of 0.94. Sage Therapeutics has a 12 month low of $4.62 and a 12 month high of $27.39. The stock has a 50-day moving average price of $6.34 and a two-hundred day moving average price of $6.93.

Sage Therapeutics (NASDAQ:SAGE) last released its quarterly earnings results on Tuesday, February 11th. The biopharmaceutical company reported ($1.56) earnings per share for the quarter, missing the consensus estimate of ($1.54) by ($0.02). Sage Therapeutics had a negative return on equity of 50.29% and a negative net margin of 317.29%. On average, sell-side analysts predict that Sage Therapeutics will post -6.46 earnings per share for the current year.

Institutional Investors Weigh In On Sage Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the stock. Picton Mahoney Asset Management raised its position in Sage Therapeutics by 126.0% in the 4th quarter. Picton Mahoney Asset Management now owns 6,423 shares of the biopharmaceutical company’s stock valued at $35,000 after buying an additional 3,581 shares during the last quarter. KLP Kapitalforvaltning AS bought a new position in Sage Therapeutics in the 4th quarter valued at $49,000. Ieq Capital LLC bought a new position in Sage Therapeutics in the 4th quarter valued at $57,000. US Bancorp DE grew its stake in Sage Therapeutics by 22.3% in the 4th quarter. US Bancorp DE now owns 12,430 shares of the biopharmaceutical company’s stock valued at $67,000 after purchasing an additional 2,268 shares during the period. Finally, Teacher Retirement System of Texas grew its stake in Sage Therapeutics by 21.6% in the 4th quarter. Teacher Retirement System of Texas now owns 13,768 shares of the biopharmaceutical company’s stock valued at $75,000 after purchasing an additional 2,446 shares during the period. 99.22% of the stock is owned by hedge funds and other institutional investors.

Sage Therapeutics Company Profile

Sage Therapeutics, Inc, a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression.